Jaap Bremer

T: +31 70 376 06 25
E: jaap.bremer@barentskrans.nl
View Jaap Bremer on LinkedIn

Jaap’s practice focuses on Intellectual Property litigation, in particular with respect to patents, trademarks and advertising. Jaap has extensive experience in infringement and invalidity litigation, as well as in parallel import, anti-counterfeiting and customs enforcement matters, particularly for clients in the pharma & life sciences, food & beverage and consumer products industries. He also regularly advises clients in non-contentious matters, including negotiation and drafting of licence and coexistence agreements.

Selected directory listings

‘The knowledge of a professor and the attitude of a lean, mean business lawyer’ – Legal 500, 2018

Sources admire his “high expertise paired with responsiveness, creativity and pragmatism,” and appreciate that he “always has the client’s interests in mind.” – Chambers Global & Europe, 2018

Clients say Jaap Bremer “turns over every stone” and is “always thinking of new opportunities, organising meetings so all options are discussed. He was also willing to listen.” – Chambers Global, 2017

“Jaap Bremer’s advocacy and technical work are excellent – he gives the clearest advice.”IAM Patent 1000, 2016

Clients say he “gets good results and always seeks out even the smallest details.” – Chambers Global & Europe 2016

Jaap Bremer is considered by commentators to be “calm, brilliant and astute.”Legal 500, 2016

Jaap Bremer is recognised in the practice area of ‘Intellectual Property: Trademarks’ by Client Choice – Client Choice

Professional activities

Member of Editorial Board EPLAW Patent Blog
Active member of the International Trademark Association (INTA)
Member of various professional associations, including EPLAW, PTMG, LES, BMM, VFenR, VvRr and MARQUES.

News and publications

Pharma update: Indirect infringement of Swiss type claims is possible

In its judgment of 3 November 2017 in the case between Merck Sharp & Dohme (‘MSD’) and Teva, the Dutch Supreme Court ruled (ECLI:NL:HR:2017:2807) that indirect infringement of a ‘Swiss type’ second medical use patent claim is possible. In addition, the Supreme Court found that there is no difference in the scope of protection of second
Read more ›

Pharma update: long-awaited final relief judgment on enforcement second medical use patent

In its final relief judgement of 5 April 2017 in Sun Pharmaceutical Industries (Europe) B.V. (“Sun“) v. Novartis et al. (“Novartis”), the District Court of The Hague ruled that Sun has directly infringed Novartis’ second medical use patent EP 1 296 689 (EP ‘689) which relates to the treatment of osteoporosis. Previously, in its interim
Read more ›
More from this specialist